Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 210

1.

Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).

Cooper-Dehoff R, Cohen JD, Bakris GL, Messerli FH, Erdine S, Hewkin AC, Kupfer S, Pepine CJ; INVEST Investigators.

Am J Cardiol. 2006 Oct 1;98(7):890-4. Epub 2006 Aug 7.

PMID:
16996868
2.

Predictors of adverse outcome among patients with hypertension and coronary artery disease.

Pepine CJ, Kowey PR, Kupfer S, Kolloch RE, Benetos A, Mancia G, Coca A, Cooper-DeHoff RM, Handberg E, Gaxiola E, Sleight P, Conti CR, Hewkin AC, Tavazzi L; INVEST Investigators.

J Am Coll Cardiol. 2006 Feb 7;47(3):547-51. Epub 2006 Jan 18.

3.

Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients--findings from the International Verapamil SR/Trandolapril Study (INVEST).

Cooper-DeHoff RM, Aranda JM Jr, Gaxiola E, Cangiano JL, Garcia-Barreto D, Conti CR, Hewkin A, Pepine CJ; INVEST Investigators.

Am Heart J. 2006 May;151(5):1072-9.

PMID:
16644338
5.

Dual therapy in hypertensive patients with coronary artery disease: the role of calcium channel blockers and beta-blockers.

Bakris GL, Cooper-Dehoff RM, Zhou Q, Kupfer S, Champion A, Pepine CJ; INVEST Investigators.

Am J Cardiovasc Drugs. 2007;7 Suppl 1:25-9.

PMID:
19845074
6.

Global differences in blood pressure control and clinical outcomes in the INternational VErapamil SR-Trandolapril STudy (INVEST).

Zineh I, Cooper-Dehoff RM, Wessel TR, Arant CB, Sleight P, Geiser EA, Pepine CJ.

Clin Cardiol. 2005 Jul;28(7):321-8.

7.

A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.

Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW; INVEST Investigators.

JAMA. 2003 Dec 3;290(21):2805-16.

PMID:
14657064
8.

Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy.

Bangalore S, Messerli FH, Cohen JD, Bacher PH, Sleight P, Mancia G, Kowey P, Zhou Q, Champion A, Pepine CJ; INVEST Investigators.

Am Heart J. 2008 Aug;156(2):241-7. doi: 10.1016/j.ahj.2008.02.023.

PMID:
18657652
9.

Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control.

Holzgreve H, Nakov R, Beck K, Janka HU.

Am J Hypertens. 2003 May;16(5 Pt 1):381-6.

PMID:
12745200
10.

Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study.

Bakris GL, Gaxiola E, Messerli FH, Mancia G, Erdine S, Cooper-DeHoff R, Pepine CJ; INVEST Investigators.

Hypertension. 2004 Nov;44(5):637-42. Epub 2004 Sep 20.

11.

INVEST revisited: review of findings from the International Verapamil SR-Trandolapril Study.

Cooper-DeHoff RM, Handberg EM, Mancia G, Zhou Q, Champion A, Legler UF, Pepine CJ.

Expert Rev Cardiovasc Ther. 2009 Nov;7(11):1329-40. doi: 10.1586/erc.09.102.

12.

A drug dose model for predicting clinical outcomes in hypertensive coronary disease patients.

Elliott WJ, Hewkin AC, Kupfer S, Cooper-DeHoff R, Pepine CJ.

J Clin Hypertens (Greenwich). 2005 Nov;7(11):654-63.

13.
14.

The fixed combination of verapamil SR/trandolapril.

Widimský J.

Expert Opin Pharmacother. 2000 Mar;1(3):515-35. Review.

PMID:
11249535
15.

Blood pressure and aortic elastic properties--verapamil SR/trandolapril compared to a metoprolol/hydrochlorothiazide combination therapy.

Breithaupt-Grögler K, Gerhardt G, Lehmann G, Notter T, Belz GG.

Int J Clin Pharmacol Ther. 1998 Aug;36(8):425-31.

PMID:
9726695
16.

Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis.

Bangalore S, Messerli FH, Franklin SS, Mancia G, Champion A, Pepine CJ.

Eur Heart J. 2009 Jun;30(11):1395-401. doi: 10.1093/eurheartj/ehp109. Epub 2009 Apr 7.

PMID:
19351690
17.

Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension.

Pepine CJ, Handberg-Thurmond E, Marks RG, Conlon M, Cooper-DeHoff R, Volkers P, Zellig P.

J Am Coll Cardiol. 1998 Nov;32(5):1228-37.

18.

Effect of strict blood pressure control on proteinuria in renal patients treated with different antihypertensive drugs.

García de Vinuesa S, Luño J, Gómez-Campderá F, Ridao N, Sánchez M, Dall'Anese C, Valderrábano F.

Nephrol Dial Transplant. 2001;16 Suppl 1:78-81.

PMID:
11369828
19.

Obesity paradox in patients with hypertension and coronary artery disease.

Uretsky S, Messerli FH, Bangalore S, Champion A, Cooper-Dehoff RM, Zhou Q, Pepine CJ.

Am J Med. 2007 Oct;120(10):863-70.

PMID:
17904457
20.

Characteristics of patients with coronary artery disease and hypertension: a report from INVEST.

Erdine S, Handberg EM, Kolb B.

Clin Cardiol. 2001 Nov;24(11 Suppl):V6-8.

Supplemental Content

Support Center